N-(2-benzyloxy-1-phenethyl)-N-(2'-methoxyethyl)amino-methane compounds are useful as tachykinin antagonists

A compound of the formula (I):

• ##STR22## wherein R.sup.1 represents hydrogen, halogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, C.sub.1-6 alkoxy, C.sub.1-4 alkyl substituted by a hydroxy or C.sub.1-4 alkoxy group, OCF.sub.3, hydroxy, trifluoromethyl, trimethylsilyl, nitro, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, COR.sup.a, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b where R.sup.a and R.sup.b are each independently hydrogen or C.sub.1-4 alkyl;
• R.sup.2 and R.sup.3 each independently represent hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkoxy substituted by a C.sub.1-4 alkoxy group, or trifluoromethyl;
• R.sup.4 represents hydrogen, halogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, C.sub.1-6 alkoxy, C.sub.1-4 alkyl substituted by a hydroxy or C.sub.1-4 alkoxy group, OCF.sub.3, hydroxy, trifluoromethyl, trimethylsilyl, nitro, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, COR.sup.a, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b where R.sup.a and R.sup.b are as previously defined;
• R.sup.5 represents hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy substituted by a C.sub.1-4 alkoxy group, or trifluoromethyl;
• R.sup.6, R.sup.7 and R.sup.8 each independently represent hydrogen or a C.sub.1-4 alkyl group optionally substituted by a hydroxy group;
• Het represents triazole optionally substituted by .dbd.O, .dbd.S or a C.sub.1-4 alkyl group, and optionally substituted by a group of the formula ZNR.sup.9 R.sup.10 where
• Z is C.sub.1-6 alkylene or C.sub.3-6 cycloalkyl;
• R.sup.9 is hydrogen or C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, or C.sub.2-4 alkyl substituted by C.sub.1-4 alkoxy or hydroxyl;
• R.sup.10 is hydrogen or C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, or C.sub.2-4 alkyl substituted by C.sub.1-4 alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S;
• or R.sup.9, R.sup.10 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C.sub.1-4 alkoxy optionally substituted by a C.sub.1-4 alkoxy or hydroxyl group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O).sub.2 or a second nitrogen atom which will be part of a NH or NR.sup.c moiety where R.sup.c is C.sub.1-4 alkyl optionally substituted by hydroxy or C.sub.1-4 alkoxy;
• or R.sup.9, R.sup.10 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
• or Z, R.sup.9 and the nitrogen atom to which they are attached form a heteroaliphatic ring to 4 to 7 ring atoms which may optionally contain an oxygen ring atom;
• or a pharmaceutically acceptable salt thereof.